Deaths attributable to carbapenem-resistant Enterobacteriaceae infections

Matthew E Falagas, Giannoula S Tansarli, Drosos E Karageorgopoulos, Konstantinos Z Vardakas, Matthew E Falagas, Giannoula S Tansarli, Drosos E Karageorgopoulos, Konstantinos Z Vardakas

Abstract

We evaluated the number of deaths attributable to carbapenem-resistant Enterobacteriaceae by using studies from around the world published before April 9, 2012. Attributable death was defined as the difference in all-cause deaths between patients with carbapenem-resistant infections and those with carbapenem-susceptible infections. Online databases were searched, and data were qualitatively synthesized and pooled in a metaanalysis. Nine studies met inclusion criteria: 6 retrospective case-control studies, 2 retrospective cohort studies, and 1 prospective cohort study. Klebsiella pneumoniae was the causative pathogen in 8 studies; bacteremia was the only infection in 5 studies. We calculated that 26%-44% of deaths in 7 studies were attributable to carbapenem resistance, and in 2 studies, which included bacteremia and other infections, -3% and -4% of deaths were attributable to carbapenem resistance. Pooled outcomes showed that the number of deaths was significantly higher in patients with carbapenem-resistant infections and that the number of deaths attributable to carbapenem resistance is considerable.

Keywords: Enterobacteriaceae; KPC; Klebsiella pneumoniae; Klebsiella pneumoniae carbapenemase; attributable deaths; attributable mortality; bacteremia; bacteria; bloodstream infection; carbapenem resistance; carbapenem-resistant Enterobacteriaceae; carbapenemase-producing; carbapenemases; deaths; infections; meta-analysis; metaanalysis; mortality; outcome; systematic review.

Figures

Figure
Figure
Selection process for studies included in a systematic review and metaanalysis of deaths attributable to carbapenem-resistant Enterobacteriaceae infections. CRE, carbapenem-resistant Enterobacteriaceae; CSE, carbapenem-susceptible Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; ESBL, extended-spectrum β-lactamase.

References

    1. Hu F, Chen S, Xu X, Guo Y, Liu Y, Zhu D, et al. Emergence of carbapenem-resistant clinical Enterobacteriaceae isolates from a teaching hospital in Shanghai, China. J Med Microbiol. 2012;61:132–6 .10.1099/jmm.0.036483-0
    1. Zarfel G, Hoenigl M, Wurstl B, Leitner E, Salzer HJ, Valentin T, et al. Emergence of carbapenem-resistant Enterobacteriaceae in Austria, 2001–2010. Clin Microbiol Infect. 2011;17:E5–8 .10.1111/j.1469-0691.2011.03659.x
    1. Daikos GL, Karabinis A, Paramythiotou E, Syriopoulou VP, Kosmidis C, Avlami A, et al. VIM-1–producing Klebsiella pneumoniae bloodstream infections: analysis of 28 cases. Int J Antimicrob Agents. 2007;29:471–3 .10.1016/j.ijantimicag.2006.11.006
    1. Daikos GL, Petrikkos P, Psichogiou M, Kosmidis C, Vryonis E, Skoutelis A, et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother. 2009;53:1868–73 .10.1128/AAC.00782-08
    1. Queenan AM, Bush K. Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev. 2007;20:440–58 .10.1128/CMR.00001-07
    1. Agodi A, Voulgari E, Barchitta M, Politi L, Koumaki V, Spanakis N, et al. Containment of an outbreak of KPC-3–producing Klebsiella pneumoniae in Italy. J Clin Microbiol. 2011;49:3986–9 .10.1128/JCM.01242-11
    1. Balkhy HH, El-Saed A, Al Johani SM, Francis C, Al-Qahtani AA, Al-Ahdal MN, et al. The epidemiology of the first described carbapenem-resistant Klebsiella pneumoniae outbreak in a tertiary care hospital in Saudi Arabia: how far do we go? Eur J Clin Microbiol Infect Dis. 2012;31:1901–9 .10.1007/s10096-011-1519-0
    1. Borer A, Eskira S, Nativ R, Saidel-Odes L, Riesenberg K, Livshiz-Riven I, et al. A multifaceted intervention strategy for eradication of a hospital-wide outbreak caused by carbapenem-resistant Klebsiella pneumoniae in southern Israel. Infect Control Hosp Epidemiol. 2011;32:1158–65 .10.1086/662620
    1. Cuzon G, Ouanich J, Gondret R, Naas T, Nordmann P. Outbreak of OXA-48–positive carbapenem-resistant Klebsiella pneumoniae isolates in France. Antimicrob Agents Chemother. 2011;55:2420–3 .10.1128/AAC.01452-10
    1. Gregory CJ, Llata E, Stine N, Gould C, Santiago LM, Vazquez GJ, et al. Outbreak of carbapenem-resistant Klebsiella pneumoniae in Puerto Rico associated with a novel carbapenemase variant. Infect Control Hosp Epidemiol. 2010;31:476–84 .10.1086/651670
    1. Pereira GH, Garcia DO, Mostardeiro M, Ogassavara CT, Levin AS. Spread of carbapenem-resistant Klebsiella pneumoniae in a tertiary hospital in São Paulo, Brazil. J Hosp Infect. 2011;79:182–3 .10.1016/j.jhin.2011.05.023
    1. Steinmann J, Kaase M, Gatermann S, Popp W, Steinmann E, Damman M, et al. Outbreak due to a Klebsiella pneumoniae strain harbouring KPC-2 and VIM-1 in a German university hospital, July 2010 to January 2011. Euro Surveill. 2011;16:19944 .
    1. Zhang R, Wang XD, Cai JC, Zhou HW, Lv HX, Hu QF, et al. Outbreak of Klebsiella pneumoniae carbapenemase 2–producing K. pneumoniae with high qnr prevalence in a Chinese hospital. J Med Microbiol. 2011;60:977–82 .10.1099/jmm.0.015826-0
    1. Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med. 2005;165:1430–5 .10.1001/archinte.165.12.1430
    1. Endimiani A, Carias LL, Hujer AM, Bethel CR, Hujer KM, Perez F, et al. Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. Antimicrob Agents Chemother. 2008;52:2680–2 .10.1128/AAC.00158-08
    1. Leavitt A, Navon-Venezia S, Chmelnitsky I, Schwaber MJ, Carmeli Y. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother. 2007;51:3026–9 .10.1128/AAC.00299-07
    1. Pournaras S, Protonotariou E, Voulgari E, Kristo I, Dimitroulia E, Vitti D, et al. Clonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains in Greece. J Antimicrob Chemother. 2009;64:348–52 .10.1093/jac/dkp207
    1. Zagorianou A, Sianou E, Iosifidis E, Dimou V, Protonotariou E, Miyakis S, et al. Microbiological and molecular characteristics of carbapenemase-producing Klebsiella pneumoniae endemic in a tertiary Greek hospital during 2004–2010. Euro Surveill. 2012;17:20088 .
    1. Chang HJ, Hsu PC, Yang CC, Kuo AJ, Chia JH, Wu TL, et al. Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: a matched case-control study. J Microbiol Immunol Infect. 2011;44:125–30 .10.1016/j.jmii.2010.06.001
    1. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase–producing K. pneumoniae. Infect Control Hosp Epidemiol. 2009;30:1180–5 .10.1086/648451
    1. Mouloudi E, Protonotariou E, Zagorianou A, Iosifidis E, Karapanagiotou A, Giasnetsova T, et al. Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase–producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect Control Hosp Epidemiol. 2010;31:1250–6 .10.1086/657135
    1. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol. 2008;29:1099–106 .10.1086/592412
    1. Falagas ME, Rafailidis PI, Kofteridis D, Virtzili S, Chelvatzoglou FC, Papaioannou V, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J Antimicrob Chemother. 2007;60:1124–30 .10.1093/jac/dkm356
    1. Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol. 2009;30:666–71 .10.1086/598244
    1. Jeon MH, Choi SH, Kwak YG, Chung JW, Lee SO, Jeong JY, et al. Risk factors for the acquisition of carbapenem-resistant Escherichia coli among hospitalized patients. Diagn Microbiol Infect Dis. 2008;62:402–6 .10.1016/j.diagmicrobio.2008.08.014
    1. Ben-David D, Kordevani R, Keller N, Tal I, Marzel A, Gal-Mor O, et al. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections. Clin Microbiol Infect. 2012;18:54–60 .10.1111/j.1469-0691.2011.03478.x
    1. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58 .10.1002/sim.1186
    1. Gaviria D, Bixler D, Thomas CA, Ibrahim SM, Kallen A, Limbago B, et al. Carbapenem-resistant Klebsiella pneumoniae associated with a long-term–care facility—West Virginia, 2009–2011. MMWR Morb Mortal Wkly Rep. 2011;60:1418–20 .
    1. Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother. 2008;52:1028–33 .10.1128/AAC.01020-07
    1. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011;17:1798–803 .10.1111/j.1469-0691.2011.03514.x
    1. Falagas ME, Karageorgopoulos DE, Nordmann P. Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. Future Microbiol. 2011;6:653–66 .10.2217/fmb.11.49
    1. Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev. 2011;35:736–55 .10.1111/j.1574-6976.2011.00268.x
    1. García-Sureda L, Doménech-Sánchez A, Barbier M, Juan C, Gascó J, Albertí S. OmpK26, a novel porin associated with carbapenem resistance in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011;55:4742–7 .10.1128/AAC.00309-11
    1. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007;60:913–20 .10.1093/jac/dkm318
    1. Vardakas KZ, Rafailidis PI, Konstantelias AA, Falagas ME. Predictors of mortality in patients with infections due to multi-drug resistant Gram negative bacteria: the study, the patient, the bug or the drug? J Infect. 2013;66:401–14 .10.1016/j.jinf.2012.10.028
    1. Rottier WC, Ammerlaan HS, Bonten MJ. Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase–producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother. 2012;67:1311–20 .10.1093/jac/dks065
    1. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twentieth- informational supplement. Document M100–S20 Vol. 30 N. Wayne (PA): The Institute; 2010.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren